Digital Therapeutics Migraine Market Report 2025

The digital therapeutics migraine market size has grown exponentially in recent years. It will grow from $1.37 billion in 2024 to $1.69 billion in 2025 at a compound annual growth rate (CAGR) of 23.4%. The growth during the historic period is driven by the increasing prevalence of migraine, the rising demand for non-drug treatments, the growing patient preference for drug-free options, the heightened focus on personalized healthcare, and the expanding availability of reimbursement for digital therapeutics.

The digital therapeutics migraine market size is expected to see exponential growth in the next few years. It will grow to $3.91 billion in 2029 at a compound annual growth rate (CAGR) of 23.3%. The growth during the forecast period is supported by the increasing adoption of wearable neuromodulation devices, greater awareness of preventive migraine care, the rise of government initiatives promoting digital health, enhanced patient engagement through gamified health platforms, and the growing partnerships between insurers and digital therapeutics providers. Key trends in the forecast period include advancements in personalized digital treatment plans, integration of mobile applications with electronic health records, progress in telemedicine-based migraine care, development of sensor-based monitoring technologies, and improvements in evidence-based digital therapies.

The growing levels of stress and lifestyle disruptions are contributing to the expansion of the digital therapeutics migraine market. Stress and lifestyle changes relate to how everyday pressures and habits affect an individual's physical and mental health. These changes are becoming more common due to the demands of modern work environments and fast-paced living, which lead to increased mental strain and interfere with healthy routines. Digital therapeutics designed for migraine support the management of stress and lifestyle issues by offering tailored behavioral strategies, monitoring potential triggers, and encouraging healthier habits that help reduce the occurrence of migraines and enhance overall well-being. For example, in February 2024, a survey conducted in the United Kingdom by Forthwithlife, a provider of at-home blood testing services, found that nearly one in five individuals aged sixteen and older experiences daily stress, with a higher percentage among women at 24.5 percent compared to 15.3 percent among men. As a result, the rise in stress and lifestyle changes is driving growth in the digital therapeutics migraine market.

Key companies within the digital therapeutics migraine space are advancing patient care through the development of technologies such as electronic prescription systems. These systems allow healthcare professionals to issue, send, and manage prescriptions digitally, offering greater precision, fewer medication-related errors, and improved efficiency in the prescribing and dispensing processes. In April 2025, Tonix Pharmaceuticals Holding Corp., a pharmaceutical company based in the United States, launched TONIX ONE, an integrated digital platform created to assist individuals in managing their migraine condition. This platform offers tailored tools, educational materials, and support services aimed at improving patient knowledge and self-care practices. It also empowers users to take an active role in their treatment, promoting consistent health management. Moreover, TONIX ONE enhances communication between patients and healthcare providers, improving coordination and the overall care experience.

In February 2024, Aptar Digital Health, LLC, a digital health company based in the United States, acquired Healint for an undisclosed sum. This acquisition allows Aptar to broaden its offerings in the field of neurology and strengthen its digital health capabilities. Healint, based in Singapore, provides digital tools for migraine management through its Migraine Buddy application, which uses artificial intelligence and sensor technology to support users in tracking and managing their symptoms.

Major players in the digital therapeutics migraine market are Pfizer Inc., Novartis AG, Eli Lilly and Company, Dr. Reddy's Laboratories Ltd., Sword Health, Biofourmis Inc., Click Therapeutics Inc., Sidekick Health, Kaia Health Software GmbH, Salvia BioElectronics, Theranica Bio-Electronics Ltd., Cefaly Technology S.A., Neurolief Ltd., Aptar Digital Health, NeuroMetrix Inc., Happify Health, Neura Health, Relivion MG, UpScriptHealth, N1-Headache.

North America was the largest region in the digital therapeutics migraine market in 2024. The regions covered in digital therapeutics migraine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the digital therapeutics migraine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Digital therapeutics for migraine are evidence-based digital solutions developed to prevent, manage, or treat migraine symptoms through software programs, offering personalized guidance and monitoring to help patients reduce attack frequency and severity. They track triggers and provide real-time feedback to enhance outcomes, complement traditional therapies, and empower patients to actively manage their migraines.

The primary product categories of digital therapeutics for migraine include software, devices, and services. Software consists of digital platforms and applications that deliver evidence-based interventions for migraine management. Patient groups include adults and children, and applications cover prevention, acute treatment, patient education, and more. These products are distributed through both online and offline channels and are utilized by key end-users such as hospitals, clinics, and home care providers.

The digital therapeutics migraine market research report is one of a series of new reports that provides digital therapeutics migraine market statistics, including the digital therapeutics migraine industry global market size, regional shares, competitors with the digital therapeutics migraine market share, detailed digital therapeutics migraine market segments, market trends, and opportunities, and any further data you may need to thrive in the digital therapeutics migraine industry. This digital therapeutics migraine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The digital therapeutics migraine market consists of revenues earned by entities by providing services such as mobile app-based migraine management services, biofeedback therapy services, wearable device integration services, nutritional guidance services, and remote monitoring programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics migraine market also includes sales of digital apps, and telehealth technology. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.